Capricor Therapeutics

Duchenne muscular dystrophy, a fatal genetic disease that wastes muscle in boys, is the focus of nearly everything at Capricor Therapeutics. The small San Diego biotech is developing deramiocel, a cell therapy made from cardiosphere-derived cells that aims to slow the decline of both heart and skeletal muscle, which would set it apart from treatments that target only one. The program has moved through a Phase 3 trial and sits before the Food and Drug Administration, with a decision expected in 2026, and that ruling is the event the entire stock hinges on. Like most single-asset biotechs, Capricor is binary: approval would validate years of work and open a market, while a rejection would gut the shares. There is little else to cushion the outcome, so the company trades as a high-stakes wager on one regulatory verdict.

On MyRWA, CAPR trades tokenized across 2 on-chain venues - see the listings below.